Propanc Biopharma, Inc. (PPCB) financial statements (2021 and earlier)

Company profile

Business Address 302/6 BUTLER STREET
CAMBERWELL, VICTORIA, 3124
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0000000
Cash and cash equivalents0000000
Receivables00000  
Other undisclosed current assets0000010
Total current assets:0000010
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment000000 
Long-term investments and receivables 0000  
Due from related parties 0000  
Deposits noncurrent assets0      
Other undisclosed noncurrent assets    00 
Total noncurrent assets:000000 
TOTAL ASSETS:0000010
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:0100000
Accounts payable 110000
Employee-related liabilities0000000
Other undisclosed accounts payable and accrued liabilities (1)(1)(0)(0)00
Debt3253100
Deferred compensation liability110111 
Derivative instruments and hedges, liabilities   0000
Due to related parties0000000
Other undisclosed current liabilities1111121
Total current liabilities:6476342
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0
Total noncurrent liabilities:0      
Total liabilities:6476342
Stockholders' equity
Stockholders' equity attributable to parent, including:(6)(4)(7)(5)(3)(3)(1)
Common stock0000100
Treasury stock, value(0)(0)(0)(0)   
Additional paid in capital48463833271716
Accumulated other comprehensive income (loss)110(0)00(0)
Retained earnings (accumulated deficit)(54)(51)(45)(38)(30)(21)18
Other undisclosed stockholders' equity attributable to parent000000(35)
Other undisclosed stockholders' equity0      
Total stockholders' equity:(6)(4)(7)(5)(3)(3)(1)
TOTAL LIABILITIES AND EQUITY:0000010

Income statement (P&L) ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Gross profit:(0)(0)(0)(0)(0)(0)(0)
Operating expenses(4)(3)(4)(6)(7)(2)(1)
Other undisclosed operating income0000000
Operating loss:(4)(3)(4)(6)(7)(2)(1)
Nonoperating expense(3)(4)(3)(2)(3)(2)(0)
Foreign currency transaction loss, before tax(1)(1)   (0)(0)
Other nonoperating expense(2)(3)(3)(2)(3)(2)(0)
Interest and debt expense(0)10(0)(1)(1)(0)
Loss from continuing operations before equity method investments, income taxes:(7)(5)(7)(8)(10)(5)(1)
Other undisclosed loss from continuing operations before income taxes(0)(0)     
Loss from continuing operations before income taxes:(7)(6)(7)(8)(10)(5)(1)
Income tax benefit0000000
Net loss:(7)(6)(7)(8)(10)(5)(1)
Other undisclosed net income (loss) attributable to parent2(0)(0)0110
Net loss available to common stockholders, diluted:(6)(6)(7)(8)(9)(3)(1)

Comprehensive Income ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Net loss:(7)(6)(7)(8)(10)(5)(1)
Comprehensive loss:(7)(6)(7)(8)(10)(5)(1)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent210(0)120
Comprehensive loss, net of tax, attributable to parent:(6)(5)(7)(8)(9)(3)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: